{"id":20585,"date":"2024-10-28T14:25:24","date_gmt":"2024-10-28T18:25:24","guid":{"rendered":"https:\/\/www.ices.on.ca\/?post_type=private_project&#038;p=20585"},"modified":"2025-08-18T14:53:23","modified_gmt":"2025-08-18T18:53:23","slug":"transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report","status":"publish","type":"private_project","link":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\/","title":{"rendered":"Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Rapid Report"},"content":{"rendered":"<p><strong>Client:<\/strong> IQVIA Solutions Canada Inc.<\/p>\n<p><strong>Project ID:<\/strong> P2024-210 \/ 2025 0980 001 000<\/p>\n<p><strong>Research Question\/Objectives:<\/strong> Transthyretin amyloidosis (ATTR amyloidosis) is a progressive and debilitating disease that can be fatal. It occurs when the transthyretin protein misfolds and accumulates as amyloid fibrils in various organs, including the heart, nerves, gastrointestinal tract, and musculoskeletal tissues.<\/p>\n<p><strong>Objectives:<\/strong><\/p>\n<ol>\n<li>Describe the demographics and clinical characteristics of patients with a diagnosis of transthyretin amyloidosis cardiomyopathy in Ontario from 2019 \u2013 2023<\/li>\n<li>Describe the incidence and prevalence of transthyretin amyloidosis cardiomyopathy in Ontario from 2019 \u2013 2023<\/li>\n<li>Describe the healthcare resource utilization (HCRU) and associated direct costs of patients with transthyretin amyloidosis cardiomyopathy in Ontario from 2019 \u2013 2023<\/li>\n<\/ol>\n<p><strong>Status:\u00a0<\/strong>Completed<\/p>\n<p><strong>Results:<\/strong> January 2026<\/p>\n\n\n<\/p>\n<p class=\"wp-block-paragraph\">\n\n\n","protected":false},"excerpt":{"rendered":"<p>Client: IQVIA Solutions Canada Inc. Project ID: P2024-210 \/ 2025 0980 001 000 Research Question\/Objectives: Transthyretin amyloidosis (ATTR amyloidosis) is a progressive and debilitating disease that can be fatal. It occurs when the transthyretin protein misfolds and accumulates as amyloid fibrils in various organs, including the heart, nerves, gastrointestinal tract, and musculoskeletal tissues. Objectives: Describe [&hellip;]<\/p>\n","protected":false},"template":"","organization_type":[],"project_status":[105],"response_type":[],"class_list":["post-20585","private_project","type-private_project","status-publish","hentry","project_status-completed"],"acf":{"project_id":"P2024-210 \/ 2025 0980 001 000","project_id_year":2024,"ices_scientist":"","principal_investigators":null,"knowledge_user":"","client":"","objectives":"","results":"","availability_of_results":"","pia_approved":null,"infographic":"","sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Rapid Report | ICES<\/title>\n<meta name=\"description\" content=\"Client: IQVIA Solutions Canada Inc. Project ID: P2024-210 \/ 2025 0980 001 000 Research Question\/Objectives: Transthyretin amyloidosis (ATTR amyloidosis)\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Rapid Report | ICES\" \/>\n<meta property=\"og:description\" content=\"Client: IQVIA Solutions Canada Inc. Project ID: P2024-210 \/ 2025 0980 001 000 Research Question\/Objectives: Transthyretin amyloidosis (ATTR amyloidosis)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-18T18:53:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\\\/\",\"name\":\"Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Rapid Report | ICES\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2024-10-28T18:25:24+00:00\",\"dateModified\":\"2025-08-18T18:53:23+00:00\",\"description\":\"Client: IQVIA Solutions Canada Inc. Project ID: P2024-210 \\\/ 2025 0980 001 000 Research Question\\\/Objectives: Transthyretin amyloidosis (ATTR amyloidosis)\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Private Sector Projects\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/services-for-researchers\\\/all-projects\\\/private-sector-projects\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Rapid Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Rapid Report | ICES","description":"Client: IQVIA Solutions Canada Inc. Project ID: P2024-210 \/ 2025 0980 001 000 Research Question\/Objectives: Transthyretin amyloidosis (ATTR amyloidosis)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\/","og_locale":"fr_FR","og_type":"article","og_title":"Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Rapid Report | ICES","og_description":"Client: IQVIA Solutions Canada Inc. Project ID: P2024-210 \/ 2025 0980 001 000 Research Question\/Objectives: Transthyretin amyloidosis (ATTR amyloidosis)","og_url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2025-08-18T18:53:23+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\/","url":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\/","name":"Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Rapid Report | ICES","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2024-10-28T18:25:24+00:00","dateModified":"2025-08-18T18:53:23+00:00","description":"Client: IQVIA Solutions Canada Inc. Project ID: P2024-210 \/ 2025 0980 001 000 Research Question\/Objectives: Transthyretin amyloidosis (ATTR amyloidosis)","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/transthyretin-amyloid-cardiomyopathy-attr-cm-rapid-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Private Sector Projects","item":"https:\/\/www.ices.on.ca\/fr\/services-for-researchers\/all-projects\/private-sector-projects\/"},{"@type":"ListItem","position":3,"name":"Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Rapid Report"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/private_project\/20585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/private_project"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/private_project"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=20585"}],"wp:term":[{"taxonomy":"organization_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/organization_type?post=20585"},{"taxonomy":"project_status","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/project_status?post=20585"},{"taxonomy":"response_type","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/response_type?post=20585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}